Novasep, viral vector producer, has signed a partnership with AstraZeneca for the production of the Oxford University COVID-19 vaccine. Novasep will produce the active substance of the vaccine in its Belgian facilities
The partnership follows the agreement between AstraZeneca and the Inclusive Alliance for Vaccines (IAV), to supply Oxford University’s COVID-19 vaccine to Europe in 2021.
Production will be carried out at Novasep’s Belgian site in Seneffe. Thanks to the biopharmaceutical ecosystem in the region, Novasep can also take advantage of additional human resources needed to achieve this project.
Michel Spagnol, President and CEO of Novasep said: “It is a great honour and pride for our teams in France and Belgium to contribute on a European scale to the fight against this pandemic. This confirms the increasing trends towards biopharmaceuticals and validates the strategic investment choices that we have been making in the production of viral vectors for several years with the support of our board. We thank AstraZeneca for its confidence in our expertise and industrial capacity. We look forward to meeting one of the major challenges of this decade”.
Image credit: CDC
